Skip to search formSkip to main contentSkip to account menu

AT 877

Known as: AT-877, AT877 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension… 
Review
2013
Review
2013
Received April 10, 2013; revised manuscript received May 27, 2013; accepted June 4, 2013; released online August 3, 2013 Time for… 
2005
2005
SummaryThe initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid… 
2001
2001
Fasudil hydrochloride (AT877, hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine hydrochloride, identical to HA1077) inhibits… 
Review
2001
Review
2001
Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and intracellular calcium antagonist. It dilated… 
Review
1998
Review
1998
Background and Purpose: It has been reported that nimodipine reduces the frequency of secondary ischemia and improves outcome… 
1994
1994
Background and Purpose The efficacy of pretreatment with the recently developed intracellular calcium antagonist AT877 against… 
1993
1993
We investigated the effects of AT‐877, a Ca2+ antagonist, on rat middle‐cerebral artery occlusion. All rats had 6‐h ischemia, and… 
Highly Cited
1992
Highly Cited
1992
With the cooperation of 60 neurosurgical centers in Japan, a prospective randomized placebo-controlled double-blind trial of a…